BioSpace News Archive

GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced an upcoming presentation of preclinical data relating to the company’s platform technology.

OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its PremiOM™ Ulcerative Colitis (UC) and Crohn’s Disease (CD) datasets, providing comprehensive, clinically-deep and representative data to support a broad assortment of research needs.

Cambrian BioPharma, a multi-asset longevity biotech, announces its Scientific Advisory Board and appointment of C. David Nicholson, PhD and Frank S. Walsh, PhD to lead.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (the “Company”) announced today the results to date of its previously announced offers (the “Exchange Offers”) to exchange the existing senior notes set forth in the table below (the “Existing Senior Notes”) for up to an aggregate principal amount of $4.0 billion.

From breakthroughs in the prevention of post-concussion syndrome to unprecedented advances in post-stroke, traumatic brain injury and spinal cell regeneration, TransMedia Group will bring major media attention to Hyperbaric Oxygen Therapy (HBOT) and one of the fields’ greatest pioneers, Veteran Hall of Famer Raymond Cralle.

Secant Group has signed an agreement with The Abigail Wexner Research Institute at Nationwide Children’s Hospital in Columbus, OH, to explore potential solutions for repairing congenital heart defects in children.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) invites individuals, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference at 12:00 ET

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) is pleased to announce that the initial clinical validation stage of its ongoing clinical study for smoldering multiple myeloma (“SMM”), in collaboration with the Mayo Clinic, has completed review and analysis of its first cohort, consisting of 187 patients and has exceeded its targeted endpoints.

Endoluxe is proud to announce that it has entered into a development agreement with Synopic to realize the advanced technology synergies of both organizations.

Olympus announced today the market launch of the Guardenia™ Contained Extraction System.